Thermo Fisher Scientific (TMO) Reports Q1 Beat with $5.11 EPS and $10.34 B in Revenue
Thermo Fisher Scientific Inc. has showcased its financial strength in the first quarter of 2024, with a slight revenue decline but commendable growth in GAAP diluted earnings per share.
Editorial disclosureRead more
All reviews, research, news and assessments of any kind on The Tokenist are compiled using a strict editorial review process by our editorial team. Neither our writers nor our editors receive direct compensation of any kind to publish information on tokenist.com. Our company, Tokenist Media LLC, is community supported and may receive a small commission when you purchase products or services through links on our website. Click here for a full list of our partners and an in-depth explanation on how we get paid.
Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, demonstrated its robust financial health in the first quarter of 2024.
Despite a slight revenue decline of 3% to $10.34 billion from the previous year’s $10.71 billion, the company has shown a commendable increase in its GAAP diluted earnings per share (EPS), which grew by 4% to $3.46.
Furthermore, the adjusted EPS saw a 2% increase, reaching $5.11. This performance underscores Thermo Fisher’s ability to navigate the complexities of the market while continuing to deliver value to its stakeholders.
Significant achievements, including launching innovative products like the Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography system and the Axiom™ PangenomiX Array marked the quarter. The company’s strategic capital deployment, highlighted by a $3.0 billion stock repurchase and an 11 percent dividend increase, reflects its strong financial position and confidence in future growth prospects.
Thermo Fisher Scientific Beats EPS and Revenue Expectations in Q1
When comparing these results against market expectations, Thermo Fisher has outperformed in several key areas. Analysts had projected an EPS of $4.71 and a revenue of $10.16 billion for the quarter. The company surpassed revenue expectations by reporting $10.34 billion and significantly exceeded the EPS forecast with an adjusted figure of $5.11.
The company’s ability to exceed analysts’ expectations indicates its robust commercial execution and operational discipline. Introducing high-impact, innovative products and expanding its service offerings have been crucial to this achievement.
TMO Ups Full-Year Revenue and Adjusted EPS Guidance for 2024
Thermo Fisher has raised its full-year revenue and adjusted EPS guidance for 2024, reflecting more robust operational performance. The company now expects revenue to be $42.3 to $43.3 billion, from the previous guidance of $42.1 to $43.3 billion.
Similarly, the adjusted EPS guidance has been raised to a new range of $21.14 to $22.02, up from the previous forecast of $20.95 to $22.00. This upward revision in guidance underscores the company’s confidence in its ability to continue delivering differentiated performance throughout the year.
Disclaimer: The author does not hold or have a position in any securities discussed in the article.
Tim Fries
Tim Fries is the cofounder of The Tokenist. He has a B. Sc. in Mechanical Engineering from the University of Michigan, and an MBA from the University of Chicago Booth School of Business. Tim served as a Senior Associate on the investment team at RW Baird's US Private Equity division, and is also the co-founder of Protective Technologies Capital, an investment firm specializing in sensing, protection and control solutions.
